VolitionRx presents early stage I solid cancer detection data for Capture-Seq at ESMO MAP conference

• VolitionRx announced early clinical validation results for its Capture-Seq liquid biopsy approach for detecting early-stage solid cancers.
• Findings were presented at the ESMO MAP conference in London on Sept. 10, 2026.
• Across multiple cohorts, the test distinguished cancer patients from healthy controls, supporting potential use in multi-cancer early detection.
• Management also positioned the platform for minimal residual disease detection, a potential follow-on market alongside screening.
• Volition estimated a $36 billion total addressable market spanning early cancer detection and MRD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609100817PR_NEWS_USPR_____LN44903) on September 10, 2026, and is solely responsible for the information contained therein.